Tag: Etranacogene dezaparvovec
CSL completes acquisition of novel gene therapy for haemophilia B
CSL Limited has wrapped up the acquisition of uniQure’s etranacogene dezaparvovec, a novel gene therapy for the treatment of haemophilia B.
Under the agreement, CSL...
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
